Download Free Medical Antiadrenergic Drugs PowerPoint Presentation

Antiadrenergic Drugs PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Pharmacology, which is titled "Antiadrenergic drugs", to know about the antiadrenergic drugs (Sympatholytics and Adrenolytics).

Tags : Pharmacology, Antiadrenergic drugs, Sympatholytics, Adrenolytics

Published on : Jul 18, 2021 | Views : 528 | Downloads : 2

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Assoc. Prof. Ivan Lambev E-mail: itlambev@mail.bg ANTIADRENERGIC DRUGS (Sympatholytics, Adrenolytics)
Slide 2-

ppt slide no 2 content not found
Slide 3-

ppt slide no 3 content not found
Slide 4-

ppt slide no 4 content not found
Slide 5-

(b1) (b1 & b2 ) Bopindolol Esmolol Oxprenolol Pindolol Propranolol Sotalol Timolol Carvedilol (antioxidant) Labetalol (b & a )  Beta-blockers (antagonists) Acebutolol Atenolol Betaxalol Bisoprolol Celiprolol Metoprolol Nebivolol Selective Non selective Mixed
Slide 6-

β-blockers with ISA (intrinsic symatho- mimetic activity) or partial agonists: Acebutolol, Celiprolol, Oxprenolol, Pindolol β-blockers with membranostabilizing activity: Acebutolol, Carvedilol, Oxprenolol, Propranolol First pass effect (hepatic metabolism, p.o. bioavailability – 22%): Oxprenolol, Pindolol, Propranolol Lipophilic drugs: more of beta-blockers Hydrophilic drug: Atenolol
Slide 7-

Lipophilic -blockers (e.g. propranolol) are well absorbed from the gut, but undergo extensive first-pass metabolism in the liver, with considerable variability. Hydrophilic -blockers (e.g. atenolol) are less completely absorbed from the gut and are eliminated unchanged by the kidney. The dose range to maintain effective plasma concentrations is narrower than for drugs which undergo metabolism and the clinical response is more predictable.
Slide 8-

Selective 1-Adrenoceptor Antagonists Metoprolol Acebutolol Atenolol
Slide 9-

Main effects of beta-blockers Antihypertensive effect Antitachyarrhythmic effect Antianginal (antistenocardic) effect “Anxiolytic” effect
Slide 10-

Antihypertensive effect Blockade of 1-adrenoceptors in the heart and reduction of the heart rate and myocardial contractility. Blockade of renal juxtaglomerular 1- receptors which reduces renin secretion. Blockade of presynaptic 2-adrenoceptors which inhibits exocytose of NA. Carvedilol and labetalol also block -receptors and produce vasodilation.
Slide 11-

Atenolol Bisoprolol Metoprolol Nebivolol Propranolol 1/2-blocking activity -blockers 15 50 25 293 1,9 S e l e c t i v i t y (55–65/min)
Slide 12-

Heart Arterioles
Slide 13-

β1-effect α-effect
Slide 14-

VDCC ROCC Receptor AP Ca2+ Ca2+ Sarcoplasmatic reticulum Cell wall (–) Beta-blockers AP – action potential, NA – noradrenaline VDCC – voltage dependant calcium channels ROCC – receptor operating calcium channels (–) Calcium blockers receptor
Slide 15-

1 tabl. daily Nebivolol Selective 1-blocker Releases NO (causes vasodilation) 24 h effect (EE/PE >90%); t1/2: 11 h
Slide 16-

1 tabl. daily F (p.o.): 90% t1/2: 11 h 24 h effect
Slide 17-

Antitachyarrhythmic effect of the beta-blockers Reduce the rate of spontaneous depo- larization of sinus and AV nodal tissue Indiations: SV and ventri- cular tachyarrhythmias. ( cAMP) - atenolol, pindolol, propranolol - only antiarrhytmic action: esmolol and sotalol
Slide 18-

Atrial flutter with a 4:1 conduction ratio. Esmolol
Slide 19-

Angina pectoris is a symptom of reversible myocardial ischaemia and is most frequently experienced as chest pain on exertion, which is relieved by rest. Pain is the consequence of an imbalance between oxygen supply and oxygen demand in the ischaemic area of myocardium. Antianginal (antistenocardic) effect
Slide 20-

“Anxiolytic” effect of β-sympatholytics
Slide 21-

ppt slide no 21 content not found
Slide 22-

ppt slide no 22 content not found
Slide 23-

Adverse reactions of b-blockers Blockade of b1-receptors may cause bradycardia, AV block, heart failure. Blockade of b2-receptors may cause bronchospasm, cold extremities, intermittent claudication (reducing peripheral blood flow) and hypoglycemia. CNS effects: sleep disturbance, dreams and hallucinations (more common with lipophilic drugs which cross the BBB).
Slide 24-

Fatigue is probably a result of reducing of cardiac output and reduced muscle perfusion in exercise Most beta-blockers raise the plasma concentration of triglycerides and lower the concentration of HDL. Sudden withdrawal syndrome: -blockers should be stopped gradually.
Slide 25-

Blockade of postsynaptic 1-receptors lowers blood pressure by: Lowering tone in arteriolar resistance vessels. Dilating venous capacitance vessels, which reduces venous return and cardiac output. Selective 1-adrenoceptor antagonists spare the presynaptic 2-adrenoceptors and do not produce reflex tachycardia.  Postsynaptic a1-blockers
Slide 26-

Postsynaptic a1-blockers Doxazosin Prazosin
Slide 27-

Prazosin – indications: - Arterial hypertension - Congestive chronic heart failure Potentially beneficial effect: an increase in HDL and a reduction in triglycerides. Adverse reactions (ARs) - Postural hypotension due to venous pooling (this can be troublesome after the first dose) - Lethargy
Slide 28-

Alfuzosin (Xatral SR®), Doxazosin, Tamsulosin (Omnic®) Selective postsynaptic alpha-1А-blockers: block alpha-1А-receptors into the smooth muscles of the prostate gland, and the prostatic part of the urethra. Indication: hyperplasia of prostate gland
Slide 29-

Carvedilol (antioxidant) Labetalol Arterial hypertension Chronic heart failure Contraindication: - cor pulmonale  Mixed beta- & alpha-antagonists
Slide 30-

 Centrally acting drugs (Antihypertensive action) - 2-agonists - I1-agonists
Slide 31-

a) α2a-agonists There are several different α2-adrenoceptor subtypes have been identiﬁed: α2a, α2b and etc. α2a-adrenoceptors appear to mediate sedation, analgesia and hypotension while the α2b-adrenoceptor mediates vasoconstriction and hypertension (i.e. postsynaptic α2-adrenoceptors are probably of the α2b subtype).
Slide 32-

Clonidine ( HCl) - xerostomia (dry mouth) - withdrawal phenomenon - sedation - postural hypotension Methyldopa The stimulation of presynaptic α2a-receptors in CNS inhibits NA release, reduces sym- pathetic influence on the vasomotor centre; reduces peripheral arterial and venous tone. (prodrug: α-methyl-NA is an α2a-agonist)
Slide 33-

Clonidine α-methyl-NA (+) Dopegyt® (α-methyl-DOPA) in liver a
Slide 34-

The stimulation of I1-receptors: in CNS reduces sympathetic tone and lowers blood pressure; in kidney inreases secretion of ANP Moxonidine Rilmenidine b) I1 (Imidazoline-1)-agonists (> t1/2: 1 time daily p.o.)
Slide 35-

 Adrenergic neuron blockers Guanethidine Reserpine Numerous ARS Rauwolfia serpentina
Slide 36-

ppt slide no 36 content not found
Slide 37-

Adrenergic neuron blockers These drugs use the active transport mechanisms for monoamines to accumulate in the adrenergic nerve terminal. Inside the cell they prevent the release of NA from vesicles.